Literature DB >> 16369169

Upregulation of oncostatin m in allergic rhinitis.

Hee Joon Kang1, Jae Seong Kang, Sang Hag Lee, Soon Jae Hwang, Sung Won Chae, Jeong-Soo Woo, Heung-Man Lee.   

Abstract

OBJECTIVES: Oncostatin M is a multifunctional cytokine belonging to the interleukin-6 family of cytokines. It has been implicated as an important modulator of lower airway remodeling in the setting of asthma. However, there have been few studies regarding a similar role for the upper airway epithelium in the setting of allergic rhinitis. This study was undertaken to investigate the expression of oncostatin M mRNA and protein in normal and allergic rhinitis nasal mucosa and to localize the expression of the oncostatin M protein in allergic rhinitis.
MATERIALS AND METHODS: Inferior turbinate mucosa samples from 20 patients with perennial allergic rhinitis and 20 matched normal control subjects were obtained. Oncostatin M mRNA was extracted from the inferior turbinate mucosae, then reverse transcriptase-polymerase chain reaction was performed and analyzed semiquantitatively. Differences in expression levels of oncostatin M protein between samples from allergic rhinitis patients and normal control subjects were analyzed through Western blot, and oncostatin M protein was localized immunohistochemically.
RESULTS: The expression levels of oncostatin M mRNA and protein were significantly upregulated in patients with allergic rhinitis mucosa. Oncostatin M protein was predominantly localized in the surface epithelium, infiltrating inflammatory cells, vascular endothelium, and submucosal glands and was more strongly expressed in the nasal mucosa of patients with allergic rhinitis than in normal control subjects.
CONCLUSIONS: Oncostatin M is expressed in the human nasal mucosa and is upregulated in the setting of allergic nasal inflammation. These results suggest a possible contribution of oncostatin M in the remodeling of the nasal mucosa in allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16369169     DOI: 10.1097/01.mlg.0000187819.89889.4a

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  10 in total

1.  Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease.

Authors:  Kathryn L Pothoven; James E Norton; Kathryn E Hulse; Lydia A Suh; Roderick G Carter; Erin Rocci; Kathleen E Harris; Stephanie Shintani-Smith; David B Conley; Rakesh K Chandra; Mark C Liu; Atsushi Kato; Nirmala Gonsalves; Leslie C Grammer; Anju T Peters; Robert C Kern; Paul J Bryce; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2015-04-01       Impact factor: 10.793

Review 2.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

3.  Role of oncostatin M in the pathogenesis of vernal keratoconjunctivitis: focus on tissue remodeling.

Authors:  Keitaro Mashimo; Ayumi Usui-Ouchi; Yousuke Ito; Rei Wakasa-Arai; Norihiko Yokoi; Satoshi Kawasaki; Akira Murakami; Akira Matsuda; Nobuyuki Ebihara
Journal:  Jpn J Ophthalmol       Date:  2021-01-06       Impact factor: 2.447

4.  Neutrophil-Derived Oncostatin M Triggers Diverse Signaling Pathways during Pneumonia.

Authors:  Katrina E Traber; Ernest L Dimbo; Anukul T Shenoy; Elise M Symer; Eri Allen; Joseph P Mizgerd; Lee J Quinton
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

5.  Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation.

Authors:  Fernando M Botelho; Javier Rangel-Moreno; Dominik Fritz; Troy D Randall; Zhou Xing; Carl D Richards
Journal:  J Immunol       Date:  2013-06-24       Impact factor: 5.422

6.  Resveratrol Downregulates Granulocyte-Macrophage Colony-Stimulating Factor-Induced Oncostatin M Production through Blocking of PI3K/Akt/NF-κB Signal Cascade in Neutrophil-like Differentiated HL-60 Cells.

Authors:  Na-Ra Han; Hi-Joon Park; Phil-Dong Moon
Journal:  Curr Issues Mol Biol       Date:  2022-01-22       Impact factor: 2.976

Review 7.  The enigmatic cytokine oncostatin m and roles in disease.

Authors:  Carl D Richards
Journal:  ISRN Inflamm       Date:  2013-12-08

8.  Dexamethasone Attenuates Oncostatin M Production via Suppressing of PI3K/Akt/NF-κB Signaling in Neutrophil-like Differentiated HL-60 Cells.

Authors:  Na-Ra Han; Seong-Gyu Ko; Hi-Joon Park; Phil-Dong Moon
Journal:  Molecules       Date:  2021-12-27       Impact factor: 4.411

9.  Oncostatin M promotes the ox-LDL-induced activation of NLRP3 inflammasomes via the NF-κB pathway in THP-1 macrophages and promotes the progression of atherosclerosis.

Authors:  Cheng Liu; Jiang Wu; Haiyun Jia; Caixia Lu; Junjun Liu; Yongxin Li; Mingjin Guo
Journal:  Ann Transl Med       Date:  2022-04

Review 10.  Remodeling of the lower and upper airways.

Authors:  Guilherme de Toledo Leme Constantino; João Ferreira de Mello
Journal:  Braz J Otorhinolaryngol       Date:  2009 Jan-Feb
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.